根据提交给美国证券交易委员会的Form 4文件显示，市值10.7亿美元的生物科技公司Enliven Therapeutics, Inc. (NASDAQ: ELVN )首席财务官Benjamin Hohl近期进行了一系列股票交易。根据InvestingPro数据，该公司整体财务健康状况评级为"良好"。2月5日，Hohl以平均价格22.52美元出售了1,000股普通股，总售价为22,524美元。

Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a biotechnology company with a market capitalization of $1.07 billion, recently executed a series of stock ...

Enliven Therapeutics, Inc. Is a Great Choice for 'Trend' Investors, Here's Why Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes ...

So should Enliven Therapeutics (NASDAQ:ELVN) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each ...

What is the current share price of Enliven Therapeutics (ELVN)? Enliven Therapeutics's (ELVN) current share price is $24.07. This constitutes a price movement of 7.60% when compared to the share price ...

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

Jane Street Group LLC lessened its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 41.9% during the 3rd quarter, HoldingsChannel reports.The firm owned 30,793 ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

BTIG initiated coverage of Enliven (ELVN) with a Buy rating and $42 price target Enliven is a precision oncology company developing targeted tyrosine kinase inhibitors directed against clinically ...

Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session. Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report ...